Innovent Biologics

35 articles with Innovent Biologics

• Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion

  6/17/2021

  Innovent Biologics, Inc. ("Innovent", HKEX: 01801), announced that the first patient has been dosed in a Phase II basket trial of taletrectinib for solid tumors containing NTRK fusion (NCT04617054).

• Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China

  6/15/2021

  Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the first subject has been successfully dosed in a phase 2 clinical trial of IBI362, a glucagon-like peptide 1 receptor and glucagon receptor dual agonist in China.

• 

  Clinical Catch-Up: June 7-11

  6/14/2021

  A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more.

• IASO Biotherapeutics and Innovent Biologics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress

  6/8/2021

  IASO Biotherapeutics and Innovent Biologics, Inc. jointly announced the delivery of an oral presentation on updated data from the Phase I study of CT103A in patients with myeloma.

• Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

  6/7/2021

  Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the results of the Phase Ia/Ib study of IBI110 were released in a poster presentation at the American Society of Clinical Oncology Annual Meeting 2021.

• Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

  6/7/2021

  Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the results of the Phase 1 study in Chinese patients with advanced solid tumors were released at the American Society for Clinical Oncology Annual Meeting 2021.

• Innovent Biologics and IASO Biotherapeutics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress

  6/7/2021

  Innovent Biologics, Inc. ("Innovent", HKEX: 01801), together with IASO Biotherapeutics (IASO Bio), jointly announced to deliver an oral presentation on updated data from the Phase I study of IBI326 in patients with relapsed/refractory multiple myeloma (R/R MM) at the European Hematology Association (EHA) Congress,

• Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021

  6/7/2021

  Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced with HUTCHMED that the results of the Phase 1b study in advanced colorectal cancer patients were released in an poster discussion at the 2021 American Association for Clinical Oncology Annual Meeting.

• Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

  6/7/2021

  Innovent Biologics, Inc together with AnHeart Therapeutics Co., Ltd jointly announced a presentation of a scientific poster entitled "Preliminary results from TRUST: A phase II clinical study to investigate Taletrectinib in treating patients with ROS1 fusion positive non-small cell lung cancer " which summarizes initial data from its ongoing trial of taletrectinib at the American Society of Clinical Oncology 2021 Annual Meeting.

• AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

  6/7/2021

  AnHeart Therapeutics Co., Ltd together with Innovent Biologics, Inc., jointly announce a presentation of a scientific poster entitled “Preliminary results from TRUST: A phase II clinical study to investigate Taletrectinib in treating patients with ROS1 fusion positive non-small cell lung cancer ” which summarizes initial data from its ongoing trial of taletrectinib at the American Society of Clinical Oncology 2021 Annual Meeting.

• Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer

  6/3/2021

  Innovent Biologics, Inc. and Eli Lilly and Company jointly announced that the National Medical Products Administration of China has approved the supplemental New Drug Application for TYVYT® in combination with gemcitabine and platinum chemotherapy as first-line therapy for people with unresectable locally advanced or metastatic squamous non-small cell lung cancer.

• Clinical Trial Results of the BCMA CAR-T Co-developed by Innovent and IASO Biotherapeutics Commented in American Society of Hematology's Medical Journal "Blood"

  6/2/2021

  Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, together with IASO Biotherapeutics (IASO Bio)

• Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China

  6/1/2021

  Innovent Biologics, Inc. and AnHeart Therapeutics Co., Ltd. jointly announce an exclusive license agreement for the co-development and commercialization of AnHeart's lead drug candidate, taletrectinib – a next-generation tyrosine kinase inhibitor designed to effectively target ROS1 and NTRK - in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

• AnHeart Therapeutics and Innovent Biologics Announce Exclusive License Agreement for Taletrectinib in Greater China

  6/1/2021

  AnHeart Therapeutics Co., Ltd. and Innovent Biologics, Inc. announced an exclusive license agreement for the co-development and commercialization of AnHeart’s lead drug candidate taletrectinib, a next-generation tyrosine kinase inhibitor designed to effectively target ROS1 and NTRK, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

• Innovent Announces First Patient Dosed in China in the Global Phase 3 Clinical Trial of Pemigatinib as the First-line Treatment of Unresectable or Metastatic Cholangiocarcinoma

  5/25/2021

  Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announces that the first patient has been successfully enrolled

• U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer

  5/18/2021

  Innovent Biologics, Inc. and Eli Lilly and Company jointly announced that the U.S. Food and Drug Administration accepted for review a Biologics License Application for sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer.

• Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/17/2021

  Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that multiple clinical data in relation to TYVYT®, pemigatinib and IBI110 will be published at the 2021 American Society of Clinical Oncology annual meeting.

• Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration

  4/28/2021

  Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first patient has been successfully dosed in a Phase 2 clinical trial for IBI302,

• Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021

  4/12/2021

  Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced with Eli Lilly and Company ("Lilly", NYSE: LLY) that the results of the Phase 3 ORIENT-3 study

• Innovent Announces Parsaclisib (IBI376) was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Follicular Lymphoma

  3/31/2021

  - Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the Center for Drug Evaluation (CDE) of China's Nation